Document:

EX-10.11

 Exhibit 10.11 

ONCORUS, INC. 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

This Amended and Restated Employment Agreement (the “Agreement”), effective as of August 8, 2018, (the
“Effective Date”) is made by and among Oncorus, Inc., a Delaware corporation (the “Company”) and Mitchell Finer Ph.D. (“Executive” and, together with the Company, the “Parties”).

 WHEREAS, the Company has employed Executive as Chief Executive Officer of the Company since March 29, 2016, pursuant
to the terms of the offer letter agreement between Executive and Company dated March 29, 2016 (the “March 2016 Agreement”); 

WHEREAS, Company desires to continue to employ Executive in a different capacity, and Executive desires to continue to provide services
to the Company, on the terms herein provided; 
 WHEREAS, this Agreement supersedes in its entirety the March 2016 Agreement; and

 NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, including the respective
covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows: 

1. Employment. 

(a) General. The Company shall employ Executive upon the terms and conditions provided herein effective as of the Effective Date.

 (b) Position and Duties. Effective on the Effective Date, Executive: (i) shall serve as Executive Chairman, with
responsibilities, duties, and authority usual and customary for such position, subject to direction by the Company’s Board of Directors (the “Board”); and (ii) agrees promptly and faithfully to comply with (x) all
reasonable and lawful directions and requests of the Board or a designated Committee thereof; and (y) all present and future policies, of the Company. At the Company’s request, Executive shall serve the Company and/or its subsidiaries and
affiliates in such other capacities in addition to the foregoing as the Company shall designate, provided that such additional capacities are consistent with Executive’s position as Executive Chairman. In the event that Executive serves in any
one or more of such additional capacities, Executive’s compensation shall not automatically be increased on account of such additional service beyond that specified in this Agreement. 

(c) Exclusivity. Except with the prior written approval of the Board (which may grant or withhold in its sole and absolute
discretion), Executive shall devote substantially all of his working time, attention, and energies to the business of the Company, except during any paid vacation or other excused absence periods. Nothing in this section prevents Executive from
(i) engaging in additional activities in connection with personal investments and community affairs, (ii) serving as a member of the board of directors of one (1) organization that is not a competitor of the Company and is approved by
the Board, and (iii) serving as an advisor, or as a member of an advisory board, to one (1) organization that is not a competitor of the Company and is approved by the Board; provided such activities do not individually or in the
aggregate interfere with the performance of Executive’s duties under this Agreement, violate the Company’s standards of conduct then in effect, or raise a conflict under the Company’s conflict of interest policies. 

 2. Term. The period of Executive’s employment under this Agreement
shall commence on the Effective Date (or such other date as mutually agreed by Company and Executive) and shall continue until Executive’s employment with the Company is terminated pursuant to Section 4 below. The phrase “Term of
Employment” as used in this Agreement shall refer to the entire period of employment of Executive by the Company. 
 3.
Compensation and Related Matters. 
 (a) Annual Base Salary. Executive shall receive a base salary at the
rate of $17,500 per month ($210,000 on an annualized basis) (as may be adjusted from time to time, the “Annual Base Salary”), subject to withholdings and deductions, which shall be paid to Executive in accordance with
the customary payroll practices and procedures of the Company. Such Annual Base Salary shall be adjusted upon completion of Series B financing to $8,750 per month ($105,000 on an annualized basis) and may be revised subsequent to the
completion of an initial public offering (“IPO”) as determined necessary or appropriate by the Board. 
 (b) Annual
Bonus. During his Term of Employment, Executive shall not be eligible to receive any discretionary annual (calendar year) bonus. 

(c) Pro-Rated CEO Bonus. Executive shall be eligible to receive a pro-rated bonus for his service as Chief Executive Officer (“CEO”) of the Company through July 23, 2018 (the “Pro-Rated CEO Bonus”). The
Pro-Rated CEO Bonus will be based on Executive’s achievement of performance objectives set by the Board during his service as CEO from January 1, 2018 through July 23, 2018. The Pro-Rated CEO Bonus, if any, will be paid on or before March 15, 2019, and will be subject to tax withholdings. 

(d) Benefits. Executive shall be eligible to participate in such employee and executive benefit plans and programs as the Company
may from time to time offer to provide to its executives, subject to the terms and conditions of such plans and programs. Notwithstanding the foregoing, nothing herein is intended, or shall be construed, to require the Company to institute or
continue any particular plan, program or benefits. While serving as an executive of the Company and on the Company’s Board, Executive shall be covered by the Company’s Directors and Officers Liability Insurance. If the Company has entered
into indemnification agreements with members of its Board of Directors, The Company will enter into the same form of indemnification agreement with Executive in his capacity as a member of the Board. 

(e) Business Expenses. The Company shall reimburse Executive for all reasonable, documented, out-of-pocket travel and other business expenses incurred by Executive in the performance of Executive’s duties to the Company in accordance with the Company’s applicable expense reimbursement
policies and procedures as are in effect from time to time. 

 4. Stock Option. As soon as reasonably practicable following the
Effective Date, the Company shall recommend to the Board that it grant to Executive, under the Oncorus, Inc. 2016 Equity Incentive Plan (the “Plan”) and his Oncorus, Inc. 2016 Equity Incentive Plan Option Agreement (the”
Option Agreement”), an option to purchase 2,128,619 shares of the Company’s common stock (the “New Option”) having an exercise price per share equal to fair market value of the Company’s common stock on
the date of grant, as determined by the Board in its sole discretion. The New Option shall be an “incentive stock option” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”)
to the maximum extent permitted by applicable law. Of the New Option (i) 354,770 shares shall vest upon the first closing of the Company’s Series B financing (“Series B Financing”), (ii) 709,540 shares shall vest in twenty-four
(24) equal monthly installments beginning with the first month following the closing of the Company’s Series B financing (“Series B Time-Based Option”), (iii) 532,155 shares shall vest on the date immediately prior to an
underwritten initial public offering of the Company’s equity securities (the “IPO”) and (iv) 532,154 shares shall vest in twenty-four (24) equal monthly installments beginning with the first month following the IPO
(“IPO Time-Based Option”), in the case of (i)–(iv) above, subject to Executive’s Continuous Service (as defined in the Plan) to the Company through each applicable vesting date. Notwithstanding the foregoing, if the
Company’ undergoes a Change in Control (as defined in the Plan), the Executive remains in Continuous Service with the Company through such date, and provided that the Executive signs, returns and allows to become effective the Release as set
forth in Section 11, then the unvested portion of the New Option that would have vested pursuant to subclause (i) and (ii) of the immediately preceding sentence shall become 100% vested immediately prior to the Change in Control. Further,
if the Executive is terminated without Cause (as defined below) after a Series B Financing or an IPO, but prior to the date on which the Series B Time-Based Option or the IPO Time-Based Option, as applicable, becomes fully vested, then the unvested
portion of the Series B Time-Based Option or IPO Time-Based Option, as applicable, shall become fully vested (for example, if Executive is terminated without Cause after the Series B Financing but before an IPO, then the unvested portion of the
Series B Time-Based Option only will become 100% vested). The New Option will be subject to all of the terms and conditions of the Plan and the Option Agreement to be entered into by the parties pursuant to which it is granted. For clarity, the
Executive will continue to vest in his current grants in the Company (Exhibit A) and Oncorus LLC (Exhibit B) pursuant to the vesting schedule applicable to each such grant. 

5. Termination.

(a) At-Will Employment. The Company and Executive acknowledge that Executive’s
employment is and shall continue to be at-will, as defined under applicable law. This means that it is not for any specified period of time and can be terminated by Executive or by the Company at any time,
with or without advance notice, and for any or no particular reason or cause. This “at-will” nature of Executive’s employment shall remain unchanged during Executive’s tenure as an employee
and may not be changed, except in an express writing signed by Executive. If Executive’s employment terminates for any reason, Executive shall not be entitled to any payments, benefits, damages, award, or compensation other than as provided in
this Agreement. 
 (b) Notice of Termination. During the Term of Employment, any termination of Executive’s employment by
the Company or by Executive (other than by reason of death) shall be communicated by written notice (a “Notice of Termination”) from one Party hereto to the other Party hereto (i) indicating the specific termination provision
in this Agreement relied upon, if any, (ii) setting forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under the provision so indicated, and (iii) specifying the

 
Date of Termination (as defined below). The failure by either the Company or Executive to set forth in the Notice of Termination all of the facts and circumstances which contribute to a showing
of Cause (as defined below) or Good Reason (as defined below) shall not waive any right of the Company or Executive hereunder or preclude the Company or Executive from asserting such fact or circumstance in enforcing their rights hereunder. 

(c) Termination Date. For purposes of this Agreement, “Date of Termination” shall mean the date of the
termination of Executive’s employment with the Company specified in a Notice of Termination. 
 6. Consequences of
Termination. 
 (a) Payments of Accrued Obligations upon all Terminations of Employment. Upon a termination of
Executive’s employment for any reason, Executive (or Executive’s estate or legal representative, as applicable) shall be entitled to receive, on or before the date required by applicable law and in any case within thirty (30) days
after Executive’s Date of Termination): (i) any portion of Executive’s Annual Base Salary earned through Executive’s Date of Termination not theretofore paid, (ii) any expenses owed to Executive under Section 3(d) above, and
(iii) any amount arising from Executive’s participation in, or benefits under, any employee benefit plans, programs, or arrangements under Section 3(c) above, which amounts shall be payable in accordance with the terms and conditions
of such employee benefit plans, programs, or arrangements. Except as otherwise set forth in Section 6(b) below, the payments and benefits described in this Section 6(a) shall be the only payments and benefits payable in the event of
Executive’s termination of employment for any reason; provided that such amount may be reduced in lieu of Executive’s repayment obligation as described in Section 6(c) if applicable. 

(b) Severance Payments upon Termination without Cause or For Good Reason. If, during the Term of Employment, Executive’s
employment is terminated by the Company without Cause or Executive resigns for Good Reason, in addition to the payments and benefits described in Section 6(a) above, and subject to Executive’s delivery to the Company of a waiver and
release of claims agreement in a form approved by the Company that becomes effective and irrevocable in accordance with Section 11(d) hereof (a “Release”), Executive will also be eligible for the following: 

(i) During the period commencing on the Date of Termination and ending twelve (12) months later or, if earlier, the date on which
Executive becomes eligible for comparable replacement coverage under a subsequent employer’s group health plan (in any case, the “COBRA Period”), subject to Executive’s valid election to continue healthcare coverage under
Section 4980B of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulation thereunder, payment by the Company of one-hundred percent (100%) of the COBRA premiums
necessary to continue Employee’s and his covered dependents’ health insurance coverage in effect for himself (and his covered dependents) on the termination date; provided, however, that if (1) any plan pursuant to which such
benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A under Treasury Regulation
Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit
without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal
monthly installments over the COBRA Period (or remaining portion thereof). 

 (ii) Notwithstanding anything in the Plan to the contrary, if the Executive’s
Continuous Service with the Company is terminated by the Company without Cause, or by Executive for Good Reason, then (1) the unvested portion of the equity awards listed on Exhibit A that are then outstanding will be accelerated such that the
portion of the equity award that would have vested in the twelve (12) month period following such termination shall become vested and exercisable effective immediately prior to the termination of Continuous Service; provided that if such
termination of Continuous Service occurs within two (2) months prior to or within twelve (12) months following a Change in Control, then the unvested portion of the equity awards listed on Exhibit A held by the Executive shall be
accelerated in full such that 100% of such awards shall become vested and exercisable effective upon the later of (a) the termination of Continuous Service or (b) immediately prior to, and contingent upon, such Change in Control; and
(2) subject in all respects to the terms of the Amended and Restated Restricted Share Purchase Agreement among the Executive, the Company and Oncorus LLC dated March 31, 2016 (the “Oncorus LLC RSPA”), the Executive shall
acquire a vested interest in 250,000 common shares of the equity award in Oncorus LLC listed on Exhibit B that are then outstanding and unvested or the remainder of the equity award in Oncorus LLC listed on Exhibit B that are then outstanding and
unvested if fewer than 250,000 shares of such equity award are unvested; provided that if such termination of Continuous Service occurs upon a Change in Control, then, notwithstanding the foregoing, the Executive shall accrue a vested interest in
100% of the equity award in Oncorus LLC listed on Exhibit B on the date of such termination. 
 (c) No Other Severance. The
provisions of this Section 6 shall supersede in their entirety any severance payment provisions in any severance plan, policy, program, or other arrangement maintained by the Company, provided, however, that this Section 6
shall not modify or supersede the terms of the Oncorus LLC RSPA. 
 (d) Company Property. Executive hereby acknowledges and
agrees that all Personal Property (as defined below) and equipment furnished to, or prepared by, Executive in the course of, or incident to, Executive’s employment, belongs to the Company and shall be promptly returned to the Company upon
termination of Executive’s employment (and will not be kept in Executive’s possession or delivered to anyone else). For purposes of this Agreement, “Personal Property” includes, without limitation, all books, manuals,
records, reports, notes, contracts, lists, blueprints, and other documents, or materials, or copies thereof (including computer files), keys, building card keys, company credit cards, telephone calling cards, computer hardware and software, cellular
and portable telephone equipment, personal digital assistant (PDA) devices, and all proprietary information relating to the business of the Company or its subsidiaries or affiliates. Following termination, Executive shall not retain any written or
other tangible material containing any proprietary information of the Company or its subsidiaries or affiliates. 
 (e) Effect of
Termination. Executive agrees that should the Executive’s employment be terminated for Cause or if Executive resigns without Good Reason, Executive shall be deemed to have resigned from any and all positions with the Company and its
subsidiaries, including any position on the Board. Executive agrees that should the Executive’s employment be terminated without Cause or if Executive resigns with Good Reason, he will no longer be Executive Chairman but the termination will
not otherwise affect his service on the Board provided that Oncorus LLC holds at least 1% of the outstanding shares of the Company. 

 (f) No Requirement to Mitigate; Survival. Executive shall not be required to
mitigate the amount of any payment provided for under this Agreement by seeking other employment or in any other manner. Notwithstanding anything to the contrary in this Agreement, the termination of Executive’s employment shall not impair the
rights or obligations of any Party. 
 (g) Definition of Cause. For purposes hereof, “Cause” shall mean any
one of the following: (i) Executive’s violation of any applicable material law or regulation respecting the business of the Company; (ii) Executive’s commission of conduct constituting, a felony or a crime involving moral
turpitude; (iii) any act of dishonesty, fraud, or misrepresentation in relation to Executive’s duties to the Company which act is materially and demonstrably injurious to the Company; (iv) Executive’s repeated failure to perform
in any material respect Executive’s duties hereunder after fifteen (15) days’ notice and an opportunity to cure such failure and a reasonable opportunity to present to the Board Executive’s position regarding any dispute relating
to the existence of such failure (other than on account of disability); (v) Executive’s failure to attempt in good faith to implement a clear and reasonable directive from the Board or to comply with any of the Company’s policies and
procedures which failure is either material or occurs after written notice from the Board; (vi) any act of gross misconduct which is materially and demonstrably injurious to the Company; or (vii) Executive’s breach of fiduciary duty
owed to the Company. 
 (h) Definition of Change in Control. For purposes hereof, “Change in Control” shall
have the meaning assigned to it in Section 13(e) of the Plan. Notwithstanding the definition of Change in Control set forth in the Plan, an IPO shall not be deemed a Change in Control. 

(i) Definition of Good Reason. For purposes hereof, “Good Reason” shall mean any one of the following:
(i) a material (greater than 10%) reduction by the Company of Executive’s Base Salary, except in the case of either an across the board reduction in salaries or a reduction of four (4) months or less due to financial exigency;
(ii) the Company’s material breach of this Agreement, or (iii) the relocation of Executive’s principal place of employment that increases Executive’s one-way commute by more than
thirty-five (35) miles, provided, that, in each case, Executive will not be deemed to have Good Reason unless (i) Executive first provides the Board with written notice of the condition giving rise to Good Reason within thirty
(30) days of its initial occurrence, (ii) the Company or the successor company fails to cure such condition within thirty (30) days after receiving such written notice (the “Cure Period”), and
(iii) Executive’s resignation based on such Good Reason is effective within thirty (30) days after the expiration of the Cure Period. 

7. Assignment and Successors. The Company shall assign its rights and obligations under this Agreement to any successor to
all or substantially all of the business or the assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of the Company, Executive, and their respective successors, assigns, personnel, and legal
representatives, executors, administrators, heirs, distributees, devisees, and legatees, as applicable. None of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments
hereunder, which may be transferred only by will, operation of law, or as otherwise provided herein. 

 8. Miscellaneous Provisions. 

(a) Non-Competition Agreement. Executive shall execute and continue to abide by the
Company’s standard form Employee Invention, Non-Disclosure, Non-Competition and Non-Solicitation Agreement entered into at
the time Executive commenced employment (the “Non-Competition Agreement”). 
 (b)
Governing Law. This Agreement shall be governed, construed, interpreted, and enforced in accordance with its express terms, and otherwise in accordance with the substantive laws of the Commonwealth of Massachusetts, without giving effect
to any principles of conflicts of law, whether of the Commonwealth of Massachusetts any other jurisdiction, and where applicable, the laws of the United States, that would result in the application of the laws of any other jurisdiction. 

(c) Validity. The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the validity
or enforceability of any other provision of this Agreement, which shall remain in full force and effect. 
 (d) Counterparts.
This Agreement may be executed in several counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement. Signatures delivered by facsimile shall be deemed effective for all
purposes. 
 (e) Entire Agreement. The terms of this Agreement, together with the
Non-Competition Agreement, are intended by the Parties to be the final expression of their agreement with respect to the employment of Executive by the Company and supersede all prior understandings and
agreements, whether written or oral, regarding Executive’s service to the Company. The Parties further intend that this Agreement, together with the Non-Competition Agreement, shall constitute the
complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, administrative, or other legal proceeding to vary the terms of this Agreement. 

(f) Amendments; Waivers. This Agreement may not be modified, amended, or terminated except by an instrument in writing signed by
Executive and a duly authorized representative of the Company. By an instrument in writing similarly executed, Executive or a duly authorized officer of the Company, as applicable, may waive compliance by the other Party with any specifically
identified provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall not operate as a waiver of, or estoppel with respect to, any other or subsequent
failure. No failure to exercise and no delay in exercising any right, remedy, or power hereunder shall preclude any other or further exercise of any other right, remedy, or power provided herein or by law or in equity. 

(g) Dispute Resolution. The parties recognize that litigation in federal or state courts or before federal or state
administrative agencies of disputes arising out of the Executive’s employment with the Company or out of this Agreement, or the Executive’s termination of employment or termination of this Agreement, may not be in the best interests of
either the 

 
Executive or the Company, and may result in unnecessary costs, delays, complexities, and uncertainty. The parties agree that any dispute between the parties arising out of or relating to the
negotiation, execution, performance or termination of this Agreement or the Executive’s employment, including, but not limited to, any claim arising out of this Agreement, claims under Title VII of the Civil Rights Act of 1964, as amended, the
Civil Rights Act of 1991, the Age Discrimination in Employment Act of 1967, the Americans with Disabilities Act of 1990, Section 1981 of the Civil Rights Act of 1966, as amended, the Family Medical Leave Act, the Employee Retirement Income
Security Act, and any similar federal, state or local law, statute, regulation, or any common law doctrine, whether that dispute arises during or after employment, shall be settled by binding arbitration with the American Arbitration Association in
accordance with the National Rules for the Resolution of Employment Disputes of the American Arbitration Association; provided however, that this dispute resolution provision shall not apply to any separate agreements between the parties that
do not themselves specify arbitration as an exclusive remedy. The location for the arbitration shall be the Boston, Massachusetts metropolitan area. Any award made by such panel shall be final, binding and conclusive on the parties for all
purposes, and judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. The arbitrators’ fees and expenses and all administrative fees and expenses associated with the filing of the arbitration
shall be borne by the Company; provided however, that at the Executive’s option, Executive may voluntarily pay up to one-half the costs and fees. The parties acknowledge and agree that their
obligations to arbitrate under this Section survive the termination of this Agreement and continue after the termination of the employment relationship between Executive and the Company. The parties each further agree that the arbitration provisions
of this Agreement shall provide each party with its exclusive remedy, and each party expressly waives any right it might have to seek redress in any other forum, except as otherwise expressly provided in this Agreement. By election
arbitration as the means for final settlement of all claims, the parties hereby waive their respective rights to, and agree not to, sue each other in any action in a Federal, State or local court with respect to such claims, but may seek to
enforce in court an arbitration award rendered pursuant to this Agreement. The parties specifically agree to waive their respective rights to a trial by jury, and further agree that no demand, request or motion will be made for trial by jury.

 (h) Enforcement. If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or future
laws, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid, or unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement
shall remain in full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance from this Agreement. Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be
added automatically as part of this Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal, valid, and enforceable. 

(i) Withholding. The Company shall be entitled to withhold from any amounts payable under this Agreement any federal, state,
local, or foreign withholding or other taxes or charges which the Company is required to withhold. The Company shall be entitled to rely on an opinion of counsel if any questions as to the amount or requirement of withholding shall arise. 

 (j) Notices. Any notices required hereunder to be in writing shall be deemed
effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by electronic mail if sent during normal business hours of the recipient, and if not, then on the next business day, (c) five (5) days after
having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.
All communications shall be sent to the Company at its primary office location and to Executive at Executive’s address as listed on the Company payroll or to Executive’s Company-issued email address, or at such other address as the Company
or Executive may designate by ten (10) days advance written notice to the other. 
 9. Prior Employment. Executive
represents and warrants that Executive’s acceptance of employment with the Company has not breached, and the performance of Executive’s duties hereunder will not breach, any duty owed by Executive to any prior employer or other person.
Executive further represents and warrants to the Company that (a) the performance of Executive’s obligations hereunder will not violate any agreement between Executive and any other person, firm, organization, or other entity;
(b) Executive is not bound by the terms of any agreement with any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous employer or other party that would be violated by Executive
entering into this Agreement and/or providing services to the Company pursuant to the terms of this Agreement; and (c) Executive’s performance of Executive’s duties under this Agreement will not require Executive to, and Executive
shall not, rely on in the performance of Executive’s duties or disclose to the Company or any other person or entity or induce the Company in any way to use or rely on any trade secret or other confidential or proprietary information or
material belonging to any previous employer of Executive. 
 10. Golden Parachute Excise Tax. 

(a) Best Pay. Any provision of this Agreement to the contrary notwithstanding, if any payment or benefit Executive would receive
from the Company pursuant to this Agreement or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to
the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then such Payment will be equal to the Reduced Amount (as defined below). The “Reduced Amount” will be either (A) the largest portion
of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (B) the entire Payment, whichever amount after taking into account all applicable federal, state, and local employment taxes,
income taxes, and the Excise Tax (all computed at the highest applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and local taxes, if applicable), results in
Executive’ s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is
required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (A) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) that results in the greatest
economic benefit for Executive. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”). Notwithstanding the foregoing, if the
Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A (as defined below) that would not otherwise be subject to taxes pursuant to Section

 
409A, then the Reduction Method and/or the Pro Rata Reduction Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:
(1) as a first priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-tax basis; (2) as a second priority,
Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or eliminated) before Payments that are not contingent on future events; and (3) as a third priority, Payments that are
“deferred compensation” within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A. 

(b) Accounting or Law Firm. The accounting firm or law firm engaged by the Company for general tax purposes as of the day prior
to the Change of Control will perform the calculations set forth in Section 10(a) above. If the firm so engaged by the Company is serving as the accountant or auditor, or lawyer for the acquiring company, the Company will appoint a nationally
recognized accounting or law firm to make the determinations required hereunder. The Company will bear all expenses with respect to the determinations by such firm required to be made hereunder. The firm engaged to make the determinations hereunder
will provide its calculations, together with detailed supporting documentation, to the Company within thirty (30) days before the consummation of a Change of Control (if requested at that time by the Company) or such other time as requested by
the Company. If the firm determines that no Excise Tax is payable with respect to a Payment, either before or after the application of the Reduced Amount, it will furnish the Company with documentation reasonably acceptable to the Company that no
Excise Tax will be imposed with respect to such Payment. Any good faith determinations of the firm made hereunder will be final, binding and conclusive upon the Company and Executive. 

11. Section 409A; Release. 

(a) General. The intent of the Parties is that the payments and benefits under this Agreement comply with or be exempt from
Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, including without limitation any such regulations or other guidance that may be issued after the Effective Date,
(“Section 409A”) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be exempt from or in compliance therewith. Notwithstanding anything herein to the contrary, in no event
shall the Company or its affiliates have any liability to Executive or to any other person in the event that the Agreement is no so exempt from or compliant with Section 409A. 

(b) Separation from Service. Notwithstanding any provision to the contrary in this Agreement: (i) no amount that
constitutes “deferred compensation” under Section 409A shall be payable pursuant to Section 6(b) above unless the termination of Executive’s employment constitutes a “separation from service” within the meaning of Section 1.409A-1(h) of the Department of Treasury Regulations (“Separation from Service”); (ii) for purposes of Section 409A, Executive’s right to receive installment payments shall
be treated as a right to receive a series of separate and distinct payments; and (iii) to the extent that any reimbursement of expenses or in-kind benefits constitutes “deferred compensation”
under Section 409A, such reimbursement or benefit shall be provided no later than December 31st of the year following the year in which the expense was incurred. The amount of expenses
reimbursed in one year shall not affect the amount eligible for reimbursement in any subsequent year. The amount of any in-kind benefits provided in one year shall not affect the amount of in-kind benefits provided in any other year. 

 (c) Specified Employee. Notwithstanding anything in this Agreement to the
contrary, if Executive is deemed by the Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A, to the extent delayed commencement of any portion of the benefits to
which Executive is entitled under this Agreement is required in order to avoid a prohibited distribution under Section 409A, such portion of Executive’s benefits shall not be provided to Executive prior to the earlier of (i) the
expiration of the six (6)-month period measured from the date of Executive’s Separation from Service with the Company or (ii) the date of Executive’s death. Upon the first business day following the expiration of the applicable
Section 409A period, all payments deferred pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive’s estate or beneficiaries), and any remaining payments due to Executive under this Agreement shall be paid
as otherwise provided herein. 
 (d) Release. Notwithstanding anything to the contrary in this Agreement, to the extent that
any payments due under this Agreement as a result of Executive’s termination of employment are subject to Executive’s execution and delivery of a Release and if Executive fails to execute the Release on or prior to the Release Expiration
Date (as defined below) or timely revokes Executive’s acceptance of the Release thereafter, Executive shall not be entitled to any payments or benefits otherwise conditioned on the Release, and (iii) in any case where Executive’s Date
of Termination and the Release Expiration Date fall in two separate taxable years, any payments required to be made to Executive that are conditioned on the Release and are treated as nonqualified deferred compensation for purposes of
Section 409A shall be made in the later taxable year. For purposes of this Section 11(d), “Release Expiration Date” shall mean the date that is twenty-one (21) days following
the date upon which the Company timely delivers the Release to Executive, or, in the event that Executive’s termination of employment is “in connection with an exit incentive or other employment termination program” (as such phrase is
defined in the Age Discrimination in Employment Act of 1967), the date that is forty-five (45) days following such delivery date. To the extent that any payments of nonqualified deferred compensation (within the meaning of
Section 409A) due under this Agreement as a result of Executive’s termination of employment are delayed pursuant to this Section 11(d), such amounts shall be paid in a lump sum on the first payroll date following the date that
Executive executes and does not revoke the Release (and the applicable revocation period has expired) or, in the case of any payments subject to Section 11(d)(iii), on the first payroll period to occur in the subsequent taxable year, if later.

 12. Reimbursement of Fees. Company shall reimburse Executive for reasonable and documented fees and
expenses of counsel incurred in connection with the negotiation of this Agreement. 
 13. Employee Acknowledgement.
Executive acknowledges that Executive has read and understands this Agreement, is fully aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in writing herein, and
has entered into this Agreement freely based on Executive’s own judgment. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date and year
first above written.     
  

			
	ONCORUS, INC.
		
	By:	 	 /s/ Luke Evnin

	Name: Luke Evnin
	Title: Chairman
	
	EXECUTIVE
		
	By:	 	 /s/ Mitchell H. Finer

	Name: Mitchell H. Finer, Ph.D.

 Exhibit A 

 

									
	 	  	 Grant Date
	  	 Number of shares
	  	 Vesting

Commencement
Date
	  	 Vesting Schedule

	Shares of Common Stock held directly by Executive	  	4/27/2016	  	1,616,125	  	1/1/2016	  	1/4th of the shares vest on the one year anniversary of the Vesting Commencement Date and the balance of the shares vest in thirty-six (36) successive equal monthly installments following
such one (1) year anniversary of the Vesting Commencement Date
					
	Shares of Common Stock held directly by Executive	  	8/29/2016	  	521,801	  	1/1/2016	  	1/4th of the shares vest on the one year anniversary of the Vesting Commencement Date and the balance of the shares vest in thirty-six (36) successive equal monthly installments following
such one (1) year anniversary of the Vesting Commencement Date
					
	Total:	  		  	2,137,926	  		  	

 Exhibit B 

 

									
	 	  	 Issue Date
	  	 Number of shares
	  	 Vesting
Commencement
Date
	  	 Vesting Schedule

	Common Shares of Oncorus LLC held directly by Executive	  	3/31/2016	  	1,000,000	  	3/31/2016	  	375,000 of the shares vest on the Vesting Commencement Date and the balance of the shares vest in thirty (30) successive equal monthly installments following the Vesting Commencement Date
					
	Shares of Common Stock of the Company held by Oncorus LLC (of which Executive holds a 35.5556% ownership interest through his ownership of Oncorus LLC)	  	4/1/2015	  	4,312,500	  	n/a	  	n/a

 FIRST AMENDMENT TO 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

FOR MITCHELL H. FINER 

This FIRST AMENDMENT TO THE AMENDED AND
RESTATED EMPLOYMENT AGREEMENT FOR MITCHELL H. FINER, PH.D. (the “Amendment”) is entered into this 14th day of November 2018, by and between Mitchell H. Finer, Ph.D. (the “Executive”) and ONCORUS, INC. (the
“Company”). 
 RECITALS 

A. The Company and the Executive have entered into that certain Amended and Restated Employment Agreement dated as of August 8, 2018 (the
“Employment Agreement”); and 
 B. The Company and the Executive desire to amend the Employment Agreement as provided
in this Amendment. 
 AGREEMENT 

The parties agree to the following: 
 1.
Amendment to Section 4. Section 4 of the Employment Agreement is hereby amended to delete such provision in its entirety and to replace such provision with the following: 

“Stock Option Award. 

(a) As soon as reasonably practicable following the Effective Date, the Company shall recommend to the Board that it grant to Executive,
under the Oncorus, Inc. 2016 Equity Incentive Plan, as the same may be amended from time to time (the “Plan”) and his Oncorus, Inc. 2016 Equity Incentive Plan Option Agreement (the “Option Agreement”), an option to
purchase 1,038,834 shares of the Company’s common stock (the “New Option”) having an exercise price per share equal to fair market value of the Company’s common stock on the date of grant, as determined by the Board in its
sole discretion. The New Option shall be an “incentive stock option” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) to the maximum extent permitted by applicable law.
Of the New Option (i) 16.66% of the shares subject to the New Option shall vest upon the first closing of the Company’s Series B financing (“Series B Financing”), (ii) 33.33% of the shares subject to the New Option shall vest
in twenty-four (24) equal monthly installments beginning with the first month following the closing of the Company’s Series B financing (“Series B Time-Based Option”), (iii) 25.00% of the shares subject to the New Option
shall vest on the date immediately prior to an underwritten initial public offering of the Company’s equity securities (the “IPO”) and (iv) 25.00% of the shares subject to the New Option shall vest in twenty-four
(24) equal monthly installments beginning with the first month following the IPO (“IPO Time-Based Option”), in the case of each of (i)–(iv) above, subject to Executive’s Continuous Service (as defined in the Plan) to
the Company through each applicable vesting date. For purposes of clarity, to the extent that any such shares subject to 

 
the New Option would have vested pursuant to the vesting schedule described above, such shares shall be vested and exercisable as of the applicable date of grant. Notwithstanding the foregoing,
if the Company’ undergoes a Change in Control (as defined in the Plan), the Executive remains in Continuous Service with the Company through such date, and provided that the Executive signs, returns and allows to become effective the Release as
set forth in Section 11, then the unvested portion of the New Option that would have vested pursuant to subclause (i) and (ii) of the immediately preceding sentence shall become 100% vested immediately prior to the Change in Control.
Further, if the Executive’s Continuous Service is terminated by the Company without Cause (as defined below) after a Series B Financing or an IPO, but prior to the date on which the Series B Time-Based Option or the IPO Time-Based Option, as
applicable, becomes fully vested, then the unvested portion of the Series B Time-Based Option or IPO Time-Based Option, as applicable, shall become fully vested (for example, if Executive’s Continuous Service is terminated without Cause after
the Series B Financing but before an IPO, then the unvested portion of the Series B Time-Based Option only will become 100% vested). The New Option will be subject to all of the terms and conditions of the Plan and the Option Agreement to be entered
into by the parties pursuant to which it is granted. 
 (b) For clarity, the Executive will continue to vest in his current grants in
the Company (Exhibit A) and Oncorus LLC (Exhibit B) pursuant to the vesting schedule applicable to each such grant.” 
 2. No Other
Amendments. Except as modified or amended in this Amendment, no other term or provision of the Employment Agreement is amended or modified in any respect. The Employment Agreement, and this Amendment, set forth the entire
understanding between the parties with regard to the subject matter hereof and supersedes any prior oral discussions or written communications and agreements. This Amendment cannot be modified or amended except in writing signed by the Executive and
an authorized officer of the Company. 
 [Signature Page Follows] 

 The parties have executed this First Amendment to the Employment Agreement for Mitchell H.
Finer, Ph.D. on the day and year first written above. 
  

			
	ONCORUS, INC.
		
	By:	 	 /s/ Luke Evnin

	Name: Luke Evnin, Ph.D.
	Title: Director
	
	EXECUTIVE
		
	By:	 	 /s/ Mitchell H. Finer

	Name: Mitchell H. Finer, Ph.D.

 SECOND AMENDMENT TO 

AMENDED AND RESTATED EMPLOYMENT AGREEMENT 

FOR MITCHELL H. FINER 

This SECOND AMENDMENT TO THE AMENDED AND
RESTATED EMPLOYMENT AGREEMENT FOR MITCHELL H. FINER, PH.D. (the “Amendment”) is entered into this sixth day of April
2020, by and between Mitchell H. Finer Ph.D. (the “Executive”) and ONCORUS, INC. (the “Company”). 

RECITALS 

A. The Company and the Executive have entered into that certain Amended and Restated Employment Agreement, dated as of August 8, 2018,
which was subsequently amended on November 14, 2018 (the “Employment Agreement”); and 
 B. The Company and the
Executive desire to further amend the Employment Agreement as provided in this Amendment. 
 AGREEMENT 

The parties agree to the following: 

1.    Amendment to Subsection 1(c). Subsection 1(c) of the Employment Agreement is hereby amended to delete such
provision in its entirety and to replace such provision with the following: 
 “(c)    Exclusivity.
Except with the prior written approval of the Board (which may grant or withhold in its sole and absolute discretion), Executive shall devote his best efforts and the necessary business time and attention to the performance of the services
customarily incident to his office and to such other services as the Board may reasonably request, except during any paid vacation or other excused absence periods. Nothing in this section prevents Executive from (i) engaging in additional
activities in connection with personal investments and community affairs, (ii) serving as a member of the boards of directors of organizations that are not competitors of the Company, and (iii) serving as an advisor, or as a member of an
advisory board, to organizations that are not competitors of the Company; provided such activities do not individually or in the aggregate interfere with the performance of Executive’s duties under this Employment Agreement as amended by
this Amendment, violate the Company’s standards of conduct then in effect, or raise a conflict under the Company’s conflict of interest policies.” 

2.    Amendment to Section 4. Section 4 of the Employment Agreement is hereby
amended to delete such Section in its entirety and to replace it with the following: 
 “4.    Stock
Option Award. As soon as reasonably practicable following the Effective Date, the Company shall recommend to the Board that it grant to Executive, under the Oncorus, Inc. 2016 Equity Incentive Plan, as the same may be amended from
time to time (the “Plan”) and his Oncorus, Inc. 2016 Equity Incentive Plan Option Agreement (the “Option Agreement”), an option to purchase 1,038,834 shares of the Company’s common stock (the “New
Option”) having an exercise price per share equal to fair market value of the Company’s common stock on the date of grant, as determined by the Board in its sole discretion. The New Option shall be an “incentive

 
stock option” within the meaning of Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) to the maximum extent permitted by applicable law. Of the
New Option (i) 16.66% of the shares subject to the New Option shall vest upon the first closing of the Company’s Series B financing (“Series B Financing”), (ii) 33.33% of the shares subject to the New Option shall vest in
twenty-four (24) equal monthly installments beginning with the first month following the closing of the Company’s Series B financing (“Series B Time-Based Option”), (iii) 25.00% of the shares subject to the New Option
shall vest on the date immediately prior to an underwritten initial public offering of the Company’s equity securities (the “IPO”) and (iv) 25.00% of the shares subject to the New Option shall vest in twenty-four
(24) equal monthly installments beginning with the first month following the IPO (“IPO Time-Based Option”), in the case of each of (i)–(iv) above, subject to Executive’s Continuous Service (as defined in the Plan) to
the Company through each applicable vesting date. For purposes of clarity, to the extent that any such shares subject to the New Option would have vested pursuant to the vesting schedule described above, such shares shall be vested and exercisable
as of the applicable date of grant. Notwithstanding the foregoing, if the Company undergoes a Change in Control (as defined in the Plan), the Executive remains in Continuous Service with the Company through such date, and provided that the Executive
signs, returns and allows to become effective the Release as set forth in Section 11, then the unvested portion of the New Option that would have vested pursuant to subclause (i) and (ii) of the immediately preceding sentence shall become
100% vested immediately prior to the Change in Control. Further, in the event that Executive’s Continuous Service with the Company is terminated by the Company without Cause (as defined below), and provided that the Executive signs, returns and
allows to become effective the Release as set forth in Section 11, then the unvested portion of the New Option shall be accelerated in full such that 100% of the shares subject to the New Option shall become vested and exercisable effective
upon such termination of the Executive’s Continuous Service. The New Option will be subject to all of the terms and conditions of the Plan and the Option Agreement to be entered into by the parties pursuant to which it is granted.” 

3.    No Other Amendments. Except as modified or amended in this Amendment, no other term or provision of the
Employment Agreement is amended or modified in any respect. The Employment Agreement, and this Amendment, set forth the entire understanding between the parties with regard to the subject matter hereof and supersedes any prior oral discussions or
written communications and agreements. This Amendment cannot be modified or amended except in writing signed by the Executive and an authorized officer of the Company. 

[Signature Page Follows] 

 The parties have executed this Second Amendment to the Amended and Restated Employment
Agreement for Mitchell H. Finer, Ph.D. on the day and year first written above. 
  

			
	ONCORUS, INC.
		
	By:	 	/s/ Ted T. Ashburn
	 Name:
 Title:
	 	 Ted T. Ashburn, M.D., Ph.D.
 Chief Executive
Officer

  
  

			
	EXECUTIVE
		
	By:	 	/s/ Mitchell H. Finer
		 	Mitchell H. Finer, Ph.D.EX-10.13

 Exhibit 10.13 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS
DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH
(I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY
DISCLOSED. 
 EXCLUSIVE LICENSE AGREEMENT 

This Agreement is made and entered into as of the 23 day of March, 2016 (“Effective Date”), by and
between the University of Pittsburgh – Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at
200 Gardner Steel Conference Center, Thackeray and O’Hara Streets, Pittsburgh, Pennsylvania 15260 (“University”), and Oncorus, Inc., a wholly owned subsidiary of Oncorus LLC, with its principal business at c/o Cooley LLP, 500 Boylston
St., 14th Floor, Boston, MA 02116-3736 (“Licensee”). 
 WHEREAS, University is the owner by assignment from the inventors of
certain Patent Rights, entitled “HSY Vectors,” developed by [***] and others of University faculty, and University has the right to grant licenses under such Patent Rights; 

WHEREAS, University desires to have the Patent Rights utilized in the public interest; 

WHEREAS, Licensee has represented to University, to induce University to enter into this Agreement, that Licensee is experienced in the
development, production, manufacture, marketing and sale of products and/or the use of similar products to the Licensed Technology and that Licensee shall commit itself to a thorough, vigorous and diligent program of exploiting the Patent Rights so
that public utilization results therefrom; and 
 WHEREAS, Licensee desires to obtain a license under the Patent Rights upon the terms and
conditions hereinafter set forth. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, the parties
hereto, intending to be legally bound, agree as follows: 
 ARTICLE 1 – DEFINITIONS 

For purposes of this Agreement, the following words and phrases shall have the following meanings: 

  
 1 

	1.1	 “Affiliate” shall mean, (i) with respect to University, any clinical or research entity that is
operated or managed as a facility under the UPMC Health System, whether or not owned by University (ii) with respect to Licensee, any entity that controls, is controlled by or is which shall be regarded as in control of another entity if it
owns or controls at least fifty percent (50%) of the shares entitled to vote in the election of directors of such entity or the ability otherwise to elect or control (through contract or otherwise) a majority of the board of directors ( or, in the
case of an entity that is not a corporation, for the election of a corresponding managing authority).*** 

  

	1.2	 “Commercially [***] Efforts” shall mean [***] efforts consistent with the commercially reasonable and
usual practice followed by [***] in pursuing the commercialization and marketing of similar products to Licensed Products, taking into account safety and efficacy, regulatory requirements and structure, and other relevant market factors.

  

	1.3	 “Field” shall mean (i) all fields of use for inventions claimed in [***] and [***] and any
Patent Rights thereof and (ii) the prevention and treatment of cancer for [***], [***], and [***] and all Patent Rights thereof. 

  

	1.4	 “Licensed Technology” shall mean any product or part thereof or service which is:

  

	 	(a)	 Covered in whole or in part by a Valid Claim in the country in which any such product or part thereof is made,
used or sold or in which any such service is used or sold; or 

  

	 	(b)	 Manufactured by using a process or is employed to practice a process which is covered in whole or in part by a
Valid Claim in the country in which any such process that is included in Licensed Technology is used or in which such product or part thereof or service is used or sold. 

 

	1.5	 “Net Sales” shall mean [***]. 

 

	1.6	 “Non-Commercial Education and Research Purposes” shall mean
use of Patent Rights (including distribution of biological materials covered by the Patent Rights) in the Field for academic research or other not-for-profit scholarly
purposes which are undertaken at a nonprofit or governmental institution that does not use the Patent Rights in the production or manufacture of products for sale or the performance of services for a fee. 

	1.7	 “Non-Royalty Sublicense Income” shall mean [***].

  

	1.8	 “Patent Rights” shall mean University intellectual property described below and assigned to
University: 

  

	 	(a)	 The United States and foreign patents and/or patent applications listed in Exhibit A; 

 

	 	(b)	 United States and foreign patents issued from the applications listed in Exhibit A and from divisionals,
continuations, continuations-in-part, reissues, renewals or substitutions of these applications; and 

 

	 	(c)	 Claims of U.S. and foreign continuation and divisional applications, and of the resulting patents, that
University has the right to license hereunder and which are directed to subject matter specifically described in the U.S. and foreign applications listed in Exhibit A. 

 

	1.9	 “Territory” shall mean worldwide. 

 

	1.10	 “Valid Claim” means a claim of (a) an issued and unexpired patent included within the Patent
Rights which has not been held unenforceable or invalid by a final, unreversed, and unappealable decision of a court or other government body competent jurisdiction, has been irretrievably abandoned or disclaimed, or has otherwise been finally
admitted or finally determined by the relevant governmental authority to be invalid, unpatentable or unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (b) a pending patent application within the Patent Rights
which has not been withdrawn, abandoned, or had all claims finally rejected and has not been pending for more than [***]. For the sake of clarity, a claim which issues more than [***] will be considered a Valid Claim so long as it has not expired.

 ARTICLE 2 – GRANT 

 

	2.1	 Subject to the terms and conditions of this Agreement, University hereby grants to Licensee, the right and
exclusive license in the Territory to make, have made, use and sell, have sold, import/export the Licensed Technology in the Field and to practice under the Patent Rights in the Field for the Term set forth in Article 10 below. University reserves
the royalty-free, nonexclusive right to practice under the Patent Rights and to use the Licensed Technology for Non-Commercial Education and Research Purposes. 

 

	2.2	 The license granted hereby is subject to the rights of the United States government, if any, as set forth in 35
U.S.C. §200, et seq. Pursuant to this law, the United States government may have acquired a nonexclusive, nontransferable, paid up license to practice or have practiced for or on behalf of the United States the inventions described in the
Patent Rights throughout the world. Pursuant to 35 U.S.C. §200, et seq. Licensed Technology produced for sale in the United States shall be substantially manufactured in the United States (unless a waiver under 35 U.S.C. §204 is granted by
the appropriate United States government agencies). 

  

	2.3	 Licensee shall have the right to enter into sublicensing arrangements with third parties through multiple tiers
for the rights, privileges and licenses granted hereunder [***]. 

  

	2.4	 In addition, Licensee shall have the right to grant sublicenses to Affiliates (without the right to grant
further sublicenses) without the consent of University and shall provide written notice of any such sublicenses to University. 

  

	2.5	 Licensee shall be responsible for screening and clearing all [***]. 

 

	2.6	 Any sublicense agreements allowed under this grant shall include a royalty rate upon sublicense Net Sales in an
amount at least equal to the rate set forth in Section 4.1(c). 

	2.7	 Licensee agrees that any sublicense granted by it shall provide that the obligations to University of Articles
2, 7, 8, 9, 10, and 13 of this Agreement shall be binding upon the sublicensee as if it were party to this Agreement. Each sublicense granted by Licensee pursuant to this Agreement shall include an audit right by University of sublicensee of the
same scope as provided in Section 5.2 with respect to Licensee. 

  

	2.8	 Licensee agrees to forward to University a copy of any and all sublicense agreements promptly upon execution
thereof, but in no event later than [***] after each such sublicense agreement has been executed by both parties thereto. 

  

	2.9	 The license granted hereunder shall not be construed to confer any rights upon Licensee by implication,
estoppel or otherwise as to any intellectual property not specifically set forth in Exhibit A hereof. 

 ARTICLE 3
– DUE DILIGENCE 
  

	3.1	 Licensee shall use Commercially [***] Efforts to bring the Licensed Technology to market as soon as
practicable, consistent with sound and reasonable business practice and judgment, and to continue active, diligent marketing efforts for the Licensed Technology throughout the Term of this Agreement. 

 

	3.2	 In addition, Licensee shall adhere to each of the following milestones: 

[***]. 
 [***]. 

 
[***]. 
  

	3.3	 Licensee shall notify University in writing of the achievement of each milestone within [***] upon the
achievement of the respective milestone. 

  

	3.4	 Licensee’s failure to perform in accordance with Section 3.1 or to fulfill on a timely basis any one
of the milestones set forth in Section 3.2 hereof shall be grounds for University to terminate this Agreement in accordance with Section 10.2 and upon termination all rights and interest to the Licensed Technology and Patent Rights shall
revert to University. 

 ARTICLE 4 – LICENSE CONSIDERATION 

 

	4.1	 In consideration of the rights, privileges and license granted by University hereunder, Licensee shall pay
royalties and other monetary consideration as follows: 

  

	 	(a)	 Initial license fee, nonrefundable and noncreditable against royalties, of Fifty Thousand Dollars ($50,000) due
immediately and payable within ten (10) business days from the Effective Date of this Agreement; 

  

	 	(b)	 Annual maintenance fees, non-refundable,
non-creditable, and not to be prorated against any other payment or royalties due, in the following amounts until the first Net Sales occur: 

(i) [***] due on the [***] anniversary of the Effective Date through the [***] anniversary of the Effective Date; and 

 (ii) [***] due on the [***] anniversary of The Effective Date and annually thereafter until
the anniversary prior to the year of the First Commercial Sale. 
  

	 	(c)	 Royalties payable in an amount equal to [***] of Net Sales due immediately and payable each calendar quarter.
Royalties shall be payable on a country-by-country and product-by-product or service-by-service basis within the Licensed Technology, commencing with the first commercial sale of such product or service in such country and ending on the expiration of
the last to survive Valid Claim within the Patent Rights covering the sale of such product or service in such country. [***]. In the event that Licensee has deemed it necessary to obtain a license from a non-Affiliate third party under any patent or
other intellectual property rights and is obligated to pay a royalty to such non-Affiliate third party or parties with respect to any Licensed Technology, then Licensee shall have the right to reduce the
applicable royalty rate payable to the University by subtracting (a) royalty rate which Licensee pays to such unaffiliated third party or parties for such patent or other intellectual property rights from (b) the royalty rate which would
otherwise have been applicable had no such license(s) from such unaffiliated third party or parties been required; provided, however, that in no event shall the effective royalty rate in a calendar quarter payable to University hereunder be less
than [***] of the Net Sales of Licensed Technology in such calendar quarter. 

  

	 	(d)	 [***] separate Milestone payments, which shall be non-refundable and
non-creditable against royalties, as follows: 

 [***]. 

For the avoidance of doubt, the [***] separate milestone payments set forth in Section 4.1(d) shall be payable only one-time and made only once regardless of the achievement of the milestone by Licensee or sublicensee. To the extent that the Licensee receives a milestone payment from a Sublicensee that is greater than the
milestone payments due under 4.1(d) i-iv the difference shall be considered a “Sublicensee Milestone Balance”, and part of Non-Royalty Sublicensing Income, and the University shall receive an
additional payment on such Sublicensee Milestone Balance consistent with Section 4.1(f) below. 

	 	(e)	 Beginning with the first Net Sales, a minimum annual royalty in the amount of $[***] per calendar year, but
only to the extent such minimum royalty is greater than the aggregate annual royalty computed in accordance with Section 4.1(c) above; and 

  

	 	(f)	 A share of Non-Royalty Sublicense Income as follow:

 [***]. 

The foregoing percentages may, at Licensees option, be reduced to [***] respectively, by making a written request and making a one-time-only payment of $[***] dollars to University on or before the first anniversary of the Effective Date. The Licensee shall agree to execute an amendment to effectuate this option if exercised. 

In the event Licensee sublicenses the Licensed Technology along with its own technology and/or intellectual property and/or that of other third
parties, Licensee shall be permitted to reasonably allocate in good faith the Non-Royalty Sublicensing Income received based upon the relative value of the various technologies and/or intellectual property to
the Licensed Technology. University shall have the right to review such determination and, if University disagrees with such determination, to notify Licensee of such disagreement in writing within [***] after Licensee notifies University of its
allocation determination. The parties shall negotiate in good faith and Licensee shall share relevant information with the University necessary to reach an agreement, within [***], on the percentage of allocation which is appropriate and reasonable.

  

	4.2	 All payments pursuant to this Agreement shall be made by check or by wire transfer in United States Dollars
without deduction or exchange, collection or other charges and directed to the address, or in the case of wire transfer, to the bank set forth in Article 11. Annual maintenance fees pursuant to Section 4.1(b) hereof are due immediately but
shall be paid on the anniversary of the Effective Date of the calendar year in which they are due. Royalty payments due pursuant to Section 4.1(c) hereof shall be paid within [***] after each March 31, June 30, September 30 and
December 31. Minimum annual royalties pursuant to Section 4.1(d) are due immediately but shall be paid by January 30 following the calendar year in which they are due. Non-Royalty Sublicense Income
payments pursuant to Section 4.1(e) hereof are due immediately but shall by paid within [***] after receipt of payment by Licensee from sub license. 

	4.3	 Taxes imposed by any foreign governmental agency on any payment to be made to University by Licensee shall be
paid by Licensee without deduction from any payment due to University hereunder. 

  

	4.4	 The balance of any payments pursuant to this Agreement; including those specified in Section 6.2; which
are overdue shall bear interest, [***], calculated from the due date until payment is received at the rate of [***]. Payment of such interest by Licensee shall not negate or waive the right of University to seek any other remedy, legal or equitable,
to which it may be entitled because of the delinquency of any payment, including, but not limited to, termination of this Agreement as set forth in Article 10. Licensee shall reimburse University for any costs and expenses incurred in connection
with collecting any overdue balance of payments with respect to Licensee’s payment and reimbursement obligations under this Agreement, including the costs of engaging counsel or a collection agency for such purpose. 

 

	4.5	 Licensee shall sell products and/or services resulting from Licensed Technology to University and for
Educational and Non-Commercial Research Purposes upon request at such price(s) and on such terms and conditions as such products and/or processes are made available to Licensee’s most favored customer.

 ARTICLE 5 – REPORTS AND AUDIT 
  

	5.1	 Within thirty (30) days after each March 31, June 30, September 30 and December 31 of
each year during the term of this Agreement beginning in the year of the first commercial sale of Licensed Technology, Licensee shall deliver to University true, accurate and detailed reports of the following information in a form as illustrated in
Exhibit B: 

  

	 	(a)	 Number of Licensed Technology products manufactured and sold by Licensee and all sublicensees;

  

	 	(b)	 Total billings for all such products; 

	 	(c)	 Accounting for all Licensed Technology services used or sold by Licensee and all sublicensees;

  

	 	(d)	 Deductions set forth in Section 1.5; 

 

	 	(e)	 Total royalties due; 

 

	 	(f)	 Name and addresses of sublicensees; and 

 

	 	(g)	 Total Non-Royalty Sublicense Income received during such calendar
quarter and total amount of payment due pursuant to 

	
	
                 Section 
4.1(e).

  

	5.2	 Licensee shall keep full, true and accurate books of account, in accordance with generally accepted accounting
principles, containing all information that may be necessary for the purpose of showing the amounts payable to University hereunder. Such books of account shall be kept at Licensee’s principal place of business. Such books of account shall be
open at all reasonable times for [***] following the end of the calendar year to which they pertain, and for [***] after the expiration or termination of this Agreement, for inspection by University or its agents for the purpose of verifying
Licensee’s royalty statement or compliance in other respects with this Agreement. The fees and expenses of University’s representatives shall be home by University; however, if an error of more than [***] of the total payments due or owing
for any year is discovered, then Licensee shall bear University’s fees and expenses. 

  

	5.3	 No later than [***] after December 31 of each calendar year during the term of this Agreement, Licensee
shall provide to University a written annual progress report, as illustrated in Exhibit C, describing Licensee’s progress on research and development, regulatory approvals, manufacturing, sublicensing, marketing and sales during the preceding
twelve-month period ending December 31. 

  

	5.4	 [***]. 

  

	5.5	 Licensee shall report to the University the date of the first commercial sale of a Licensed Technology within
[***] of occurrence in each country. 

 ARTICLE 6 – PATENT PROSECUTION 

 

	6.1	 University has or shall apply for, seek prompt issuance of and maintain during the term of this Agreement the
Patent Rights in the United States and in such foreign countries as may be designated by Licensee in a written notice to University within a reasonable time in advance of the required foreign filing dates. Licensee shall have the opportunity to
advise and cooperate with University in the prosecution, filing and maintenance of such patents. Licensee shall notify University immediately if, at any ·time during the term of this Agreement, Licensee or any of its sublicensees does not
qualify as a “small entity” as provided by the United States Patent and Trademark Office. 

  

	6.2	 Licensee shall be responsible for all fees and costs, including attorneys’ fees, relating to the filing,
prosecution, maintenance, and post grant proceedings relating to the Patent Rights associated with US provisional [***] and PCT application [***]. Licensee shall be responsible for [***] of all fees and costs, including attorneys’ fees,
relating to the filing, prosecution, maintenance, and post grant proceedings relating to the Patent Rights associated with provisional application [***], PCT application [***], and US Application [***], whether incurred prior to or after the
Effective Date. Such fees and costs incurred by University prior to the Effective Date in the amount of $[***] (“Pre-agreement Expenses”) are due on the Effective Date and shall be paid by Licensee
to University as follows: $[***] due within [***] of the Effective Date: and thereafter $[***] due every [***] for a total of [***] equal payments Fees and costs incurred after the Effective Date, or fees and costs incurred before the Effective Date
which are not included in the Pre-agreement Expenses stated above, shall be paid by Licensee within [***] after receipt of University’s invoice therefor. Additionally, Licensee shall be liable to
University for all of University’s out-of-pocket filing, prosecution, and maintenance costs (including all attorneys’ fees and costs), for any and all patent
prosecution and maintenance actions that will be taken by patent counsel after the term of this Agreement but in response to any instructions that were sent during the term of this Agreement from University to patent counsel relating to the Patent
Rights associated with US provisional [***] and PCT application [***]. Licensee shall be liable to University for [***]% of all University’s out-of-pocket filing,
prosecution, 

 and maintenance costs (including all attorneys’ fees and costs), for any and all patent
prosecution and maintenance actions that will be taken by patent counsel after the term of this Agreement but in response to any instructions that were sent during the term of this Agreement from University to patent counsel relating to the Patent
Rights associated with provisional application [***], PCT application [***], and US Application [***]. Payments pursuant to this Section 6.2 are not creditable against royalties or any other payment due to University under this Agreement. If
Licensee does not agree to bear the expense of filing patent applications in any country in which University wishes to obtain patent protection, then University may file and prosecutes applications at its own expense and any license granted
hereunder shall exclude such countries. 
 ARTICLE 7 – INFRINGEMENT ACTIONS 

 

	7.1	 Licensee shall inform University promptly in writing of any alleged infringement of the Patent Rights by a
third party and of any available evidence thereof. 

  

	7.2	 During the term of this Agreement, Licensee shall have the right, but shall not be obligated, to prosecute at
its own expense all infringements of the Patent Rights (or interference actions) in the Field and in the Territory if Licensee has notified University in writing of its intent to prosecute; provided, however, that such right to bring such an
infringement action shall remain in effect only for so long as the license granted herein remains exclusive. In furtherance of such right, University hereby agrees that Licensee may include University as a party plaintiff in any such suit, without
expense to University. The total cost of any such infringement action commenced or defended solely by Licensee shall be home by Licensee and University shall receive a [***]. Licensee shall indemnify University against any order for costs that may
be made against University in such proceedings. 

  

	7.3	 If within [***] after having been notified of any alleged infringement, Licensee shall have been unsuccessful
in persuading the alleged infringer to desist and shall not have brought and shall not be diligently prosecuting an infringement action, or if Licensee shall notify University at any time prior thereto of its intention not to bring suit against any
alleged infringer, then, and in those events only, University shall have the right, but shall not be obligated, to prosecute at its own expense any infringement of the Patent Rights, and University may, for such purposes, use the name of Licensee as
party plaintiff. University shall bear all costs and expenses of any such suit. [***]. 

	7.4	 In the event that a declaratory judgment action alleging invalidity or infringement of any of the Patent Rights
shall be brought against University, Licensee, at its option, shall have the right, within [***] after commencement of such action, to intervene and take over the sole defense of the action at its own expense. 

 

	7.5	 In any infringement suit either party may institute to enforce the Patent Rights pursuant to this Agreement,
the other party shall, at the request and expense of the party initiating such suit, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, information, samples,
specimens, and other evidence upon request. 

 ARTICLE 8 – INDEMNIFICATION/INSURANCE/LIMITATION OF LIABILITY

  

	8.1	 Licensee shall at all times during the term of this Agreement and thereafter indemnify, defend and hold
University, its trustees, officers, faculty members, employees and affiliates (“Indemnified Parties”) harmless against all claims and expenses, including legal expenses and reasonable attorneys’ fees, arising out of the death of or
injury to any person or persons or out of any damage to property or the environment, and against any other claim, proceeding, demand, expense and liability of any kind brought by a third party whatsoever resulting from: (i) the production,
manufacture, sale, use, lease, consumption or advertisement of the Licensed Technology, (ii) the practice by Licensee or sublicensee of the Patent Rights; or (iii) arising from or relating to this License Agreement. Licensee shall provide
this defense and indemnity whether or not any Indemnified Party, either jointly or severally, is named as a party defendant and whether or not any Indemnified Party is alleged to be negligent or otherwise responsible for any injuries to person or
property. The obligation of Licensee to defend and indemnify as set forth herein shall survive termination of this Agreement and shall not be limited by any other limitation of liability elsewhere in this Agreement. 

	8.2	 Licensee shall obtain and carry in full force and effect liability insurance which shall protect Licensee and
University in regard to events covered by Section 8.1 above, as provided below: 

 [***] 

The University of Pittsburgh is to be named as an additional insured with respect to insurance policies identified in Sections 8.2(a) and
8.2(b) above. Certificates of insurance evidencing the coverage required above shall be filed with University’s Office of Technology Management, 200 Gardner Steel Conference Center, Thackeray & O’Hara Streets, Pittsburgh, PA
15260, no later than [***] after execution of this Agreement and on or before July 1 of each subsequent year during the Term of this Agreement. Such certificates shall provide that the insurer will give University not less than [***] advance
written notice of any material changes in or cancellation of coverage. 
  

	8.3	 UNIVERSITY, AND ITS AGENTS AND/OR EMPLOYEES, MAKE NO REPRESENTATION AND EXTEND NO WARRANTIES OF ANY KIND,
EITHER EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, AND VALIDITY OF PATENT RIGHTS CLAIMS, ISSUED OR PENDING. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED AS A REPRESENTATION OR
WARRANTY THAT THE PRACTICE BY LICENSEE OF THE LICENSE GRANTED HEREUNDER SHALL NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY. UNIVERSITY ADDITIONALLY DISCLAIMS ALL OBLIGATIONS AND LIABILITIES ON THE PART OF UNIVERSITY, ITS AGENTS AND/OR EMPLOYEES
FOR DAMAGES, INCLUDING, BUT NOT LIMITED TO, DIRECT, INDIRECT, SPECIAL AND CONSEQUENTIAL DAMAGES, ATTORNEYS’ AND EXPERTS’ FEES, AND COURT COSTS (EVEN IF UNIVERSITY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES, FEES OR COSTS), ARISING
OUT OF OR IN CONNECTION WITH THIS AGREEMENT, INCLUDING THE MANUFACTURE, USE OR SALE OF THE PRODUCT(S) AND SERVICE(S) LICENSED UNDER THIS AGREEMENT. LICENSEE ASSUMES ALL RESPONSIBILITY AND LIABILITY FOR LOSS OR DAMAGE CAUSED BY A PRODUCT THAT IS
MANUFACTURED, USED OR SOLD BY LICENSEE (INCLUDING SUBLICENSEE SALES) WHICH IS LICENSED TECHNOLOGY HEREUNDER. 

 ARTICLE 9 – ASSIGNMENT 

This Agreement is not assignable without the prior written consent of the other Party, which shall not be unreasonably withheld, delayed or conditioned; and
any attempt to do so shall be null and void; provided however, that Licensee may assign this Agreement without the University’s prior written consent to (i) an Affiliate or (ii) a third party in connection with a merger or
consolidation or the transfer or sale of all or substantially all of the assets or business of Licensee to which this Agreement relates, provided that the assignee agrees in writing in advance of such assignment to be bound by the terms of this
Agreement to the same extent as Licensee in advance of such assignment, and the assumption agreement is promptly delivered to University. 

ARTICLE 10 – TERM AND TERMINATION 
  

	10.1	 Term. The term of this Agreement shall continue until the expiration of the last to expire Valid Claim anywhere
in the Territory, unless terminated early pursuant to Section 10.2 or 10.3 below. 

  

	10.2	 University shall have the right to terminate this Agreement, upon written notice, if: 

 

	 	(a)	 Licensee defaults in the performance of any of the obligations herein contained and such default has not been
cured within [***] after receiving written notice thereof from University; or 

  

	 	(b)	 Licensee ceases to carry out its business, files for bankruptcy or insolvency protection under applicable law,
applies for or consents to the appointment of a trustee, receiver or liquidator of its assets or seeks relief under any law for the aid of debtors, in which case such proceeding is not dismissed within [***]. 

 

	10.3	 Licensee may terminate this Agreement upon [***] prior written notice to University and upon payment of all
amounts accrued or due to the University through the effective date of termination, including patent cost reimbursement pursuant to Section 6.2 hereof. 

	10.4	 [***]. 

  

	10.5	 Upon termination of this Agreement, neither party shall be released from any obligation that accrued prior to
the effective date of such termination. Licensee and any sublicensee may, however, after the effective date of such termination, sell all Licensed Technology which Licensee produced prior to the effective date of such termination, provided that
Licensee shall pay to University the royalties thereon as required by Article 4 hereof and submit the reports required by Article 5 hereof. 

ARTICLE 11 – NOTICES 
  

	11.1	 Any notice or communication pursuant to this Agreement shall be sufficiently made or given if sent by certified
or registered mail, postage prepaid, or by overnight courier, with proof of delivery by receipt, addressed to the address below or as either party shall designate by written notice to the other party, or if in accordance with Section 11.3.

 In the case of University: 

Associate Vice Chancellor for Technology Management and Commercialization 

Office of Technology Management 

University of Pittsburgh 
 200
Gardner Steel Conference Center 
 Thackeray & O’Hara Streets 

Pittsburgh, PA 15260 
 In the
case of Licensee: 
 Oncorus, Inc. 

Cooley, LLP (c/o Marc Recht) 

500 Boylston St., 
 Boston, MA
02116 
 Attn: General Counsel 

	11.2	 Any payments to University hereunder by wire transfer shall be directed as follows: 

[***] 
 The Licensee shall be
responsible for all applicable fees and costs relating to any wire transfer, to include translation fees, without any deduction of such fees from amounts due to the University pursuant to this Agreement. 

 

	11.3	 All invoices to Licensee generated by University under this Agreement will be sent electronically, via e-mail, in PDF format, unless instructed otherwise by Licensee in writing. 

 ARTICLE
12 – AMENDMENT, MODIFICATION 
 This Agreement may not be amended or modified except by the execution of a written instrument
signed by the University’s Executive Vice Chancellor, or its successor and/or designated University employee having signatory authority, and an officer of Licensee. In connection with any agreed upon amendment or modification of this Agreement
pursuant to this Article 12, Licensee maybe required to pay an Amendment Fee. 
 ARTICLE 13 – MISCELLANEOUS 

 

	13.1	 This Agreement shall be construed and interpreted in accordance with the laws of the Commonwealth of
Pennsylvania. The forum for any action relating to this Agreement, including those brought against individuals such as University employees or agents, shall be the Courts of Allegheny County, Pennsylvania, or, if in a federal proceeding, the United
States District Court for the Western District of Pennsylvania. 

  

	13.2	 The parties acknowledge that this Agreement sets forth the entire understanding and intentions of the parties
hereto as to the subject matter hereof and supersedes all previous representations, negotiations, or understandings between the parties and/or its employees or agents, whether written or oral, regarding the subject matter of this Agreement.

  

	13.3	 The parties acknowledge that they consulted, or had the opportunity to investigate and/or consult, with their
legal counsel and/or other advisors with respect to the Patent Rights, Licensed Technology, and the terms of this Agreement. 

	13.4	 The parties agree that this Agreement constitutes an arm’s length business transaction and does not create
a fiduciary relationship. 

  

	13.5	 Nothing contained in this Agreement shall be construed as conferring upon either party any right to use in
advertising, publicity or other promotional activities any name, trade name, trademark, or other designation of the other party, including any contraction, abbreviation, or simulation of any of the foregoing. Without the express written approval of
the other party, neither party shall use any designation of the other party in any promotional activity associated with this Agreement or the Licensed Technology. Neither party shall issue any press release or make any public statement in regard to
this Agreement without the prior written approval of the other party. 

  

	13.6	 Licensee agrees that with respect to the performance of this Agreement or the practice of the rights granted by
the University hereunder, it shall comply with any and all applicable United States export control laws and regulations, as well as any and all embargoes and/or other restrictions imposed by the Treasury Department’s Office of Foreign Asset
Controls. Specifically, Licensee is responsible for pre-screening and ensuring that all sublicensees are not listed as a restricted party under US Export Control laws and regulations prior to entering into any
sublicense agreement under Section 2 and shall automatically terminate such sublicense agreements when such sublicensee is subsequently listed as a restricted party. 

 

	13.7	 [***]. 

  

	13.8	 If one or more of the provisions of this Agreement shall be held invalid, illegal or unenforceable, the
remaining provisions shall not in any way be affected or impaired thereby. In the event any provision is held illegal or unenforceable, the parties shall use reasonable efforts to substitute a valid, legal and enforceable provision which, insofar as
is practical, implements purposes of the provision held invalid, illegal or unenforceable. 

  

	13.9	 Failure at any time to require performance of any of the provisions herein shall not waive or diminish a
party’s right thereafter to demand compliance therewith or with any other provision. Waiver of any default shall not waive any other default. A patty shall not be deemed to have waived any rights hereunder unless such waiver is in writing and
signed by a duly authorized officer of the party making such waiver. 

	13.10	 Licensee acknowledges that University is free to publish the results of the research activities of its faculty,
staff and students, even though such publication may involve the Patent Rights or Licensed Technology. University agrees to submit to Licensee any .proposed publication or presentation regarding the subject matter specifically described in the
Patent Rights for prior review by Licensee at least [***] before its submittal for publication or its presentation. Licensee may, within [***] after receipt of such proposed publication, request that such proposed publication be delayed not more
than [***] in order to allow for protection of intellectual property rights in which case University shall so delay publication. 

  

	13.11	 Licensee shall mark all Licensed Technology with applicable U.S. and foreign patent numbers in accordance with
the applicable laws of the countries in which Licensed Technology is used or sold. 

 [remainder of page intentionally left
blank] 

 IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind
the party to this Agreement and have set their hands and seals as of the date set forth on the first page hereof. 
  

			
	UNIVERSITY OF PITTSBURGH — OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
		
	By	 	 /s/ Marc S. Malandro

		 	Marc S. Malandro, Ph.D., CLP, RTTP Associate Vice Chancellor for Technology Management and Commercialization
	
	Oncorus, Inc.
		
	By:	 	 /s/ Kenneth Greenberg

	Name:	 	Kenneth Greenberg
	Title:	 	Director

 EXHIBIT A 

PATENT RIGHTS FOR EXCLUSIVE LICENSE AGREEMENT BETWEEN 

THE UNIVERSITY OF PITTSBURGH AND ONCORUS, INC. 
  

	[***]	 

 EXHIBIT B 

SAMPLE ROYALTY REPORT 
 Licensee name: 

Reporting period: 
 Date of report: 

Royalty Reporting Form 
  

									
	 Product
	  	 No. units sold

(including
 sublicense)
	  	 Gross sales
	  	 Allowable

deductions
	  	 Net Sales

	Product name	  		  		  		  	
	Product name	  		  		  		  	
	Product name	  		  		  		  	
	Product name	  		  		  		  	
	Total	  		  		  		  	

  

					
	 Total net sales
	  	$	             	 
	 Royalty rate
	  			
	 Royalty due
	  	$	 	 

 Total royalty due:
$                                     

 

	Name	 and addresses of sublicensees: 

Total non-royalty sublicense income:
$                                 

 

	Report	 prepared by: 

	Title:	 

	Date:	 

 EXHIBIT C 

SAMPLE PROGRESS REPORT 
 Licensee name:

 Report date: 
 Technology title: 

Progress Report 
  

	A.	 Date development plan initiated and time period covered by this report 

 

	B.	 Development report 

  

	 	1.	 Activities, e.g., research and development, regulatory approvals, manufacturing, sublicensing, marketing and
sales, etc., completed since last report including the object and parameters of the development, when initiated, when completed and the results 

  

	 	2.	 Activities currently under investigations, i.e., ongoing activities including object and parameters of such
activities, when initiated, and projected date of completion 

  

	C.	 Future development activities 

 

	 	1.	 Activities to be undertaken before next report including, but not limited to, the type and object of any
studies conducted and their projected starting and completion dates 

  

	 	2.	 Estimated total development time remaining before a product will be commercialized 

 

	D.	 Changes to initial development plan 

 

	 	1.	 Reasons for change 

  

	 	2.	 Variables that may cause additional changes 

 

	E.	 Items to be provided if applicable: 

 

	 	1.	 Information relating to product that has become publicly available, e.g., published articles, competing
products, patents, etc. 

  

	 	2.	 Development work being performed by third parties other than Licensee to include name of third party, reasons
for use of third party, planned future use of third parties including reasons why and type of work 

  

	 	3.	 Update of competitive information trends in industry, government compliance, and market plan

 FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “First Amendment”) is made as of the 30th day of June, 2016, by and between the University of Pittsburgh—Of the Commonwealth System of Higher Education, a non-profit corporation organized and
existing under the laws of the Commonwealth of Pennsylvania (“University”) and Oncorus, Inc., with its principal business at c/o Cooley LLP, 500 Boylston St., 14th Floor, Boston, MA 02116-3736 (“Licensee”). 

WHEREAS, University and Licensee have previously entered into an Exclusive License Agreement with effective date of as of March 23, 2016
(the “Agreement”); and 
 WHEREAS, the parties wish to amend the Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and sufficiency which are hereby
acknowledged, the parties hereby agree as follows: 
  

	1.	 Amendments to Agreement. 

 

	 	(a)	 Article 1.1 of Agreement is hereby deleted and replaced in its entirety with the following;

 “Affiliate” shall mean, (i) with respect to University, any clinical or research entity that is operated
or managed as a facility under the UPMC Health System, whether or not owned by University (ii) with respect to Licensee, any entity that is at least fifty percent (50%) owned or controlled by Licensee, where control means that Licensee is
entitled to vote in the election of directors of such entity or Licensee has the ability otherwise to elect or control (through contract or otherwise) a majority of the board of directors (or, in the case of an entity that is not a corporation, for
the election of a corresponding managing authority). 
  

	 	(b)	 Article 4.1(f)(iii) of Agreement is hereby deleted and replaced in its entirety with the following:

 [***]. 
  

	 	(c)	 Article 4.2 of Agreement is hereby deleted and replaced in its entirety with the following:

 “All payments pursuant to this Agreement shall be made by check or by wire transfer in United States Dollars
without deduction or exchange, collection or other charges and directed to the address, of in the case of wire transfer, to the bank set forth in Article 11. Annual maintenance fees pursuant to Section 4.1(b) hereof are due immediately but
shall be paid on the anniversary of the Effective Date of the calendar year in which they are due. Royalty payments due pursuant to Section 4.1(c) hereof shall be paid within [***] after each March 31, June 30, September 30 and
December 31. Milestone payments pursuant to Article 4.1(d) shall be paid within [***] of milestone event date. Minimum annual royalties pursuant to Section 4.1(e) are due immediately but shall be paid by January 30 following the calendar
year in which they are due. Non-Royalty Sublicense Income payments pursuant to Section 4.1(f) hereof are due immediately but shall by paid within [***] after receipt of payment by Licensee from
sublicense.” 
  

	 	(d)	 Article 8.2 of the Agreement is hereby deleted and replaced in its entirety with the following;

 “Licensee shall obtain and carry in full force and effect liability insurance which shall protect Licensee and
University in regard to events covered by Section 8.1 above, as provided below: 
 [***] 

The Products Liability coverage required by 8.2(b) above shall be seemed ho later than [***] prior to the earlier of the first commercial sale
of Licensed Technology by Licensee or sublicensees, or :first use of Patent Rights or Licensed Technology in humans by Licensee or sublicensees. The University of Pittsburgh is to be named as an additional insured with respect to insurance policies
identified in Sections 8.2(a) 

 and 8.2(b) above. Except as specifically set forth above for Products Liability coverage,
certificates of insurance evidencing the coverage required above shall be filed with University’s Office of Technology Management; 200 Gardner Steel Conference Center, Thackeray & O’Hara Streets, Pittsburgh, PA 15260, no later
than [***] after execution of this First Amendment and annually thereafter. Such certificates shall provide that the insurer will give University not less than [***] advance written notice of any material changes in or cancellation of
coverage.” 
  

	3.	 Miscellaneous. 

 

	 	(a)	 Except as specifically amended above, all terms of the Agreement shall remain in full force arid effect. To the
extent that there are any inconsistencies between the terms of the Agreement and the terms of this First Amendment, the terms of this First Amendment shall prevail in effect. 

 

	 	(b)	 The parties acknowledge that this First Amendment and the Agreement set forth the entire understanding and
intentions of the parties hereto as to the subject matter hereof and supersedes all previous understandings between the parties, written or oral, regarding such subject matter. 

[remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind
the party to this Agreement and hereto have executed this First Amendment as of the date first written above. 
  

									
	Reviewed and approved by OGC	  		  	 UNIVERSITY OF PITTSBURG – OF

	University of Pittsburgh	  		  	THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
	By:	  	 /s/ Illegible
	  		  		  	
					
	Date:	  	7/20/16	  		  		  	
		  		  		  	By:	  	 /s/ Marc S. Malandro

				
		  		  	                	  	 Marc S. Malandro, Ph.D., CLP, RTTP

Associate Vice Chancellor for Technology Management and Commercialization

				
		  		  		  	 Oncorus, Inc.

					
		  		  		  	By:	  	 /s/ Thomas Chalberg

		  		  		  	Name:	  	Thomas W. Chalberg, Jr.
		  		  		  	Title:	  	Chief Operating Officer

 SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Second Amendment”) is made as of the 4th day of November, 2016, by and between the University of Pittsburgh — Of the Commonwealth System of Higher Education, a non-profit corporation organized
and existing under the laws of the Commonwealth of Pennsylvania (“University”) and Oncorus, Inc., a Delaware corporation with its principal place of business at 450 Kendall Street, Cambridge, MA 02142 (“Licensee”). 

WHEREAS, University and Licensee have previously entered into an Exclusive License Agreement with effective date of March 23, 2016, as
previously amended by the parties on June 30, 2016 (the “Agreement”); and 
 WHEREAS, the parties wish to further
amend the Agreement as set forth herein. 
 NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the
receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 
 1. Amendment Fee. The Licensee shall pay University an
Amendment Fee in the amount of $[***] which shall be due immediately upon Licensee’s execution of this Second Amendment and payable within [***] thereof. 

2. Pre-Agreement Patent Expenses for Pitt Ref No. [***]. The Licensee shall pay University $[***] associated with the
fees and costs, including attorneys’ fees, relating to the filing, prosecution, maintenance, and post grant proceedings relating to the Patent Rights associated with US provisional [***]. The amount shall be due immediately upon Licensee’s
execution of this Second Amendment and payable within [***] thereof. 
  

	1.	 Amendments to the Agreement. 

 

	 	a.	 Article 1.10 of Agreement is hereby deleted and replaced in its entirety with the following:

	 	““Valid Claim” means a claim of (a) an issued and unexpired patent included within the Patent Rights which has not been held unenforceable or invalid by a final, unreversed, and unappealable decision
of a court or other government body of competent jurisdiction, has not been irretrievably abandoned or disclaimed, or has not otherwise been finally admitted or finally determined by the relevant governmental authority to be invalid, unpatentable or
unenforceable, whether through reissue, reexamination, disclaimer or otherwise, or (b) a pending patent application within the Patent Rights which has not been withdrawn, abandoned, or had all claims finally rejected and has not been pending
for more than [***] of the applicable application or from the PCT filling date for applications derived from a PCT. For the sake of clarity, a claim which issues more [***] will be considered a Valid Claim so long as it has not expired.”

  

	 	b.	 Article 3.2 of Agreement is hereby amended by the addition of the following: 

“[***].” 
  

	 	c.	 Exhibit A of the Agreement is hereby deleted and replaced in its entirety by the attached Exhibit A.

  

	4.	 Miscellaneous. 

 

	 	(a)	 Except as specifically amended above, all terms of the Agreement shall remain in full force and effect. To the
extent that there are any inconsistencies between the terms of the Agreement and the terms of this Second Amendment, the terms of this Second Amendment shall prevail in effect. 

 

	 	(b)	 The parties acknowledge that this Second Amendment and the Agreement set forth the entire understanding and
intentions of the parties hereto as to the subject matter hereof and supersedes all previous understandings between the parties, written or oral, regarding such subject matter. 

[Remainder of this page is left intentionally blank.] 

 IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind
the party to this Agreement and hereto have executed this Second Amendment as of the date first written above. 
  

			
	UNIVERSITY OF PITTSBURGH — OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
		
	By:	 	 /s/ Marc S. Malandro

		 	Marc S. Malandro, Ph.D., CLP, RTTP
		 	Vice Chancellor for Technology
		 	Management and Commercialization

 Reviewed and approved by OGC 

        University of Pittsburgh 
  

			
	By:	 	 /s/ Illegible

		
	Date:	 	11/11/16

  

			
	LICENSEE
		
	By:	 	 /s/ Cyrus D. Mozayeni

	Name:	 	Cyrus D. Mozayeni, MD
	Title:	 	President & Chief Business Officer

 EXHIBIT A 

PATENT RIGHTS FOR SECOND AMENDMENT TO LICENSE AGREEMENT 

BETWEEN 
 THE UNIVERSITY
OF PITTSBURGH AND ONCORUS, INC. 
  

	[***]	 

 THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT 

This THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Third Amendment”) is made as of the 29th day of October, 2019, by and between the University of Pittsburgh — Of the Commonwealth System of Higher Education, a non-profit corporation organized
and existing under the laws of the Commonwealth of Pennsylvania (“University”) and Oncorus, Inc., a Delaware corporation with its principal place of business at 50 Hampshire Street, Suite, 401, Cambridge, MA 02139
(“Licensee”). 
 WHEREAS, University and Licensee have previously entered into an Exclusive License Agreement with
effective date of March 23, 2016, as previously amended by the parties on June 30, 2016 and November 4, 2016 (the “Agreement”); and 

WHEREAS, the parties wish to further amend the Agreement as set forth herein. 

NOW, THEREFORE, in consideration of the foregoing and for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereby agree as follows: 
  

	1.	 Amendments to the Agreement. 

 

	 	(a)	 Article 1.3 of the Agreement is hereby deleted and replaced in its entirety with the following:

 “Field” shall mean (i) all fields of use for inventions claimed in [***] and all Patent Rights thereof
and (ii) the prevention and treatment of cancer for inventions claimed in [***] and all Patent Rights thereof.” 
  

	 	(b)	 The first sentence of Article 6.2 of the Agreement is hereby deleted and replaced in its entirety with the
following: 

 “Licensee shall be responsible for all fees and costs, including attorneys’ fees, relating to the
filing prosecution, maintenance, and post grant proceedings relating to the Patent Rights associated with [***].” 
  

	 	(c)	 The fifth sentence of Article 6.2 of the Agreement is hereby deleted and replaced in its entirety with the
following: 

 “Additionally, Licensee shall be liable to University for all of University’s out-of-pocket filing, prosecution, and maintenance costs (including all attorneys’ fees and costs), for any and all patent prosecution and maintenance actions that will
be taken by patent counsel after the term of this Agreement but in response to any instructions that were sent during the term of this Agreement from University to patent counsel relating to the Patent Rights associated with [***].” 

	2.	 Miscellaneous. 

 

	 	(a)	 Except as specifically amended above, all terms of the Agreement shall remain in full force and effect. To the
extent that there are any inconsistencies between the terms of the Agreement and the terms of this Third Amendment, the terms of this Third Amendment shall prevail in effect. 

 

	 	(b)	 The parties acknowledge that this Third Amendment and the Agreement set forth the entire understanding and
intentions of the parties hereto as to the subject matter hereof and supersedes all previous understandings between the parties, written or oral, regarding such subject matter. 

[Remainder of page intentionally left blank] 

 IN WITNESS WHEREOF, the parties represent and warrant that each has the authority to bind
the party to this Agreement and hereto have executed this Third Amendment as of the date first written above. 
  

			
	UNIVERSITY OF PITTSBURGH — OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
		
	By:	 	/s/ Evan Facher
		 	Evan Facher, Ph.D., MBA
		 	 Director, Innovation Institute
 Vice
Chancellor for Innovation and
 Entrepreneurship

  

			
	LICENSEE
		
	By:	 	/s/ John McCabe
		 	John McCabe
		 	 Chief Financial Officer
 Oncorus,
Inc.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]